Lv4
520 积分 2024-10-18 加入
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor
11小时前
待确认
Faculty Opinions recommendation of Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor
11小时前
已关闭
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
11小时前
待确认
Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
1天前
待确认
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
1天前
待确认
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
1天前
待确认
Dealing with KRAS G12C inhibition in non-small cell lung cancer (NSCLC) – biology, clinical results and future directions
1天前
待确认
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
1天前
待确认
Tumor PD-L1 induces β2m ubiquitylation and degradation for cancer cell immune evasion
1天前
待确认
Liquid–Liquid Phase Separation: Mechanisms, Roles, and Implications in Cellular Function and Disease
1个月前
已完结
皖公网安备34019202002308
